Inclusion Criteria:

- Age: 18～70yrs

- Signed informed consent

- Confirmed malignant tumor patients by histopathological or cytological diagnosis,
suitable for chemotherapy with carboplatin combined with taxol or cyclophosphamide
combined with pharmorubicin

- Karnofsky score ≥70

- Life expectancy >3 months

- WBC≥3,500 per cubic milliliter, ANC≥1,500 per cubic milliliter, PLT≥100,000 per cubic
milliliter

- Normal coagulation function, no evidences of hemorrhage

- Normal liver, heart, kidney function

Exclusion Criteria:

- Pregnant or lactating females

- Proven active infectious diseases (e.g. viral hepatitis, TB)

- Not adequately controlled infections

- Known hypersensitivity to filgrastim or any other components of the study drug

- Unstable or uncontrolled cardiac disease or hypertension

- Currently participated in any other clinical trials

- Patients with previous or expected to receive systemic radiotherapy

- Evidence of metastatic disease in bone marrow, brain, et al

- Alcoholic or drug abusers

- Other conditions which in the opinion of the investigator preclude enrollment into
the study